Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)
| Autor: | Michael A. Liss, Matthew R. Cooperberg, Atreya Dash, Todd M. Morgan, Marshall D. Brown, Yingye Zheng, Andrew A. Wagner, Daniella Bianchi-Frias, James D. Brooks, Peter R. Carroll, Ian M. Thompson, Lisa F. Newcomb, Daniel W. Lin, Peter S. Nelson, Martin E. Gleave, Michael D. Fabrizio, Anna Faino |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
PCA3 Cancer Research medicine.medical_specialty Biopsy Urology 030232 urology & nephrology TMPRSS2 Article 03 medical and health sciences Prostate cancer 0302 clinical medicine Transcriptional Regulator ERG Antigens Neoplasm Prostate Biomarkers Tumor medicine Humans Watchful Waiting Aged medicine.diagnostic_test Receiver operating characteristic business.industry Serine Endopeptidases active surveillance Prostatic Neoplasms biomarkers Cancer Middle Aged prostate cancer medicine.disease 3. Good health TMPRSS2:ERG medicine.anatomical_structure ROC Curve Oncology 030220 oncology & carcinogenesis Neoplasm Grading business Erg |
| Zdroj: | Prostate cancer and prostatic diseases |
| ISSN: | 1476-5608 1365-7852 |
| Popis: | Background: For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. This study examined the association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification. Methods: Urine was collected at baseline, 6, 12, and 24 months in the multi-institutional Canary Prostate Active Surveillance Study (PASS), and PCA3 and T2:ERG levels were quantitated. Reclassification was an increase in Gleason score or ratio of biopsy cores with cancer to ≥34%. The association of biomarker scores, adjusted for common clinical variables, with short-term and long-term reclassification was evaluated. Discriminatory capacity of models with clinical variables alone or with biomarkers was assessed using receiver operating characteristic (ROC) curves and decision curve analysis (DCA). Results: 782 men contributed 2,069 urine specimens. After adjusting for PSA, prostate size and ratio of biopsy cores with cancer, PCA3 but not T2:ERG was associated with short-term reclassification at the first surveillance biopsy (OR=1.3; 95% CI 1.0–1.7, p=0.02). The addition of PCA3 to a model with clinical variables improved area under the curve from 0.743 to 0.753 and increased net benefit minimally. After adjusting for clinical variables, neither marker, nor marker kinetics, was associated with time to reclassification in subsequent biopsies. Conclusions: PCA3 but not T2:ERG was associated with cancer reclassification in the first surveillance biopsy, but has negligible improvement over clinical variables alone in ROC or DCA analyses. Neither marker was associated with reclassification in subsequent biopsies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink